NZ630239A - Methods of treating melanoma - Google Patents
Methods of treating melanomaInfo
- Publication number
- NZ630239A NZ630239A NZ630239A NZ63023913A NZ630239A NZ 630239 A NZ630239 A NZ 630239A NZ 630239 A NZ630239 A NZ 630239A NZ 63023913 A NZ63023913 A NZ 63023913A NZ 630239 A NZ630239 A NZ 630239A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- treating melanoma
- individual
- melanoma
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763391P | 2013-02-11 | 2013-02-11 | |
| US13/791,841 US9149455B2 (en) | 2012-11-09 | 2013-03-08 | Methods of treating melanoma |
| PCT/US2013/072877 WO2014123612A1 (en) | 2013-02-11 | 2013-12-03 | Methods of treating melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630239A true NZ630239A (en) | 2017-08-25 |
Family
ID=51300036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630239A NZ630239A (en) | 2013-02-11 | 2013-12-03 | Methods of treating melanoma |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2953622B1 (enExample) |
| JP (3) | JP6388880B2 (enExample) |
| KR (1) | KR102148551B1 (enExample) |
| CN (2) | CN109200031A (enExample) |
| BR (1) | BR112015019064A8 (enExample) |
| CA (1) | CA2900668A1 (enExample) |
| ES (1) | ES2872328T3 (enExample) |
| HK (1) | HK1218506A1 (enExample) |
| IL (1) | IL240388B (enExample) |
| MX (1) | MX377729B (enExample) |
| NZ (1) | NZ630239A (enExample) |
| WO (1) | WO2014123612A1 (enExample) |
| ZA (1) | ZA201505956B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| HUE048876T2 (hu) | 2011-05-09 | 2020-08-28 | Mayo Found Medical Education & Res | Rákos megbetegedések kezelése |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| WO2015095842A2 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| CN107073132B (zh) | 2014-10-06 | 2021-08-27 | 梅约医学教育与研究基金会 | 载体-抗体组合物及其制备和使用方法 |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| JP6921802B2 (ja) * | 2015-08-18 | 2021-08-18 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | キャリア結合剤組成物およびそれを作製および使用する方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| WO2017165440A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109890419A (zh) * | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| AU2017324947A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| CA3076919A1 (en) * | 2017-10-03 | 2019-04-11 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20130281376A1 (en) * | 2010-10-08 | 2013-10-24 | Abraxis Bioscience, Llc | Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer |
-
2013
- 2013-12-03 WO PCT/US2013/072877 patent/WO2014123612A1/en not_active Ceased
- 2013-12-03 MX MX2015010312A patent/MX377729B/es active IP Right Grant
- 2013-12-03 ES ES13874757T patent/ES2872328T3/es active Active
- 2013-12-03 CN CN201811025229.5A patent/CN109200031A/zh active Pending
- 2013-12-03 CN CN201380075292.9A patent/CN105120859B/zh active Active
- 2013-12-03 JP JP2015556938A patent/JP6388880B2/ja active Active
- 2013-12-03 HK HK16106468.2A patent/HK1218506A1/zh unknown
- 2013-12-03 CA CA2900668A patent/CA2900668A1/en not_active Abandoned
- 2013-12-03 NZ NZ630239A patent/NZ630239A/en unknown
- 2013-12-03 KR KR1020157024822A patent/KR102148551B1/ko active Active
- 2013-12-03 BR BR112015019064A patent/BR112015019064A8/pt not_active Application Discontinuation
- 2013-12-03 EP EP13874757.1A patent/EP2953622B1/en active Active
-
2015
- 2015-08-06 IL IL240388A patent/IL240388B/en active IP Right Grant
- 2015-08-18 ZA ZA2015/05956A patent/ZA201505956B/en unknown
-
2017
- 2017-11-07 JP JP2017214523A patent/JP6470381B2/ja active Active
-
2019
- 2019-01-17 JP JP2019006038A patent/JP2019056014A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN109200031A (zh) | 2019-01-15 |
| BR112015019064A8 (pt) | 2019-11-12 |
| JP2018016660A (ja) | 2018-02-01 |
| EP2953622A4 (en) | 2016-09-21 |
| EP2953622A1 (en) | 2015-12-16 |
| KR20150119177A (ko) | 2015-10-23 |
| JP2016513097A (ja) | 2016-05-12 |
| KR102148551B1 (ko) | 2020-08-26 |
| CN105120859A (zh) | 2015-12-02 |
| MX2015010312A (es) | 2015-11-18 |
| WO2014123612A1 (en) | 2014-08-14 |
| HK1218506A1 (zh) | 2017-02-24 |
| ES2872328T3 (es) | 2021-11-02 |
| ZA201505956B (en) | 2016-11-30 |
| CN105120859B (zh) | 2018-10-09 |
| IL240388A0 (en) | 2015-09-24 |
| IL240388B (en) | 2020-07-30 |
| JP6470381B2 (ja) | 2019-02-13 |
| BR112015019064A2 (pt) | 2017-07-18 |
| EP2953622B1 (en) | 2021-03-24 |
| JP6388880B2 (ja) | 2018-09-12 |
| JP2019056014A (ja) | 2019-04-11 |
| MX377729B (es) | 2025-03-11 |
| CA2900668A1 (en) | 2014-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| NZ602382A (en) | Methods of treatment of hepatocellular carcinoma | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| NZ759766A (en) | Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety | |
| NZ630392A (en) | Methods of treating lung cancer | |
| LT2720698T (lt) | 4-((1r,3s)-6-chlor-3-fenil-indan-1-il)-1,2,2-trimetil-piperazino ir jo druskų įvedimo būdas, skirtas šizofrenijos gydymui | |
| NZ717490A (en) | Methods of treating cancer | |
| NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| IN2015DN01156A (enExample) | ||
| HK1218506A1 (zh) | 治療黑素瘤的方法 | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| BR112015032758A2 (pt) | nanopartículas poliméricas de docetaxel para o tratamento de câncer | |
| MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| PH12014501579A1 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
| MX2017013047A (es) | Tratamiento de dolor. | |
| BR112015004469A2 (pt) | sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares | |
| GEP201706644B (en) | Insecticidal water-in-oil (w/o) formulation | |
| PH12019550033A1 (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| WO2014026013A3 (en) | Methods for maintaining or improving health, well-being and/or a physiological function in a subject | |
| BR112014029308A2 (pt) | um método de melhorar a função hepática | |
| WO2013188876A3 (en) | Methods for modulating kallikrein (klkb1) expression | |
| WO2013038200A3 (en) | Neurodevelopmental disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2018 BY AJ PARK Effective date: 20180118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2019 BY AJ PARK Effective date: 20180903 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2020 BY COMPUTER PACKAGES INC Effective date: 20191119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2021 BY CPA GLOBAL Effective date: 20201030 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2022 BY CPA GLOBAL Effective date: 20211028 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2023 BY CPA GLOBAL Effective date: 20221108 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2024 BY CPA GLOBAL Effective date: 20231102 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251031 |